At a glance
ClinicalIndex Comparison Record- ✓Prior participation in and completion of Study JCAV, JCAY, or other enzastaurin clinical pharmacology/biopharmaceutics studies
- ✓Advanced or metastatic cancer with no other life-prolonging therapy available
- ✓Measurable or detectable lesions
- ✓Treated, stable brain cancer allowed
- ✕Treatment with other experimental drugs within 30 days (excluding enzastaurin)
- ✕Pregnant or breastfeeding
- ✕Active untreated CNS tumors
- ✕Second malignancy (except adequately treated skin cancer or cancer-free >2 years)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Study of Oral Enzastaurin HCl in Patients With Advanced or Metastatic Malignancies
In Brief
A Phase 2 clinical trial evaluating enzastaurin for Neoplasms and Cancer. Completed, enrolled 23 participants across 1 site.
Detailed Summary
This study will collect further basic safety data on participants with cancer treated with enzastaurin. This study is not open to the public. The purpose of the this study is to extend the clinical experience of participants who complete enzastaurin therapy per clinical pharmacology and biopharmaceutics studies conducted by Eli Lilly and Company and who may benefit from continued enzastaurin therapy.
Study Details
Timeline
Interventions
500 milligrams (mg), oral, daily, six 42-day cycle and subsequent cycles or until participants met study discontinuation criteria of progressive disease or unacceptable toxicity